egfp

EG1, a novel specific inhibitor of Pax2 transcription activation, targets the DNA binding domain and inhibits embryonic kidney development.

Enhanced Green Fluorescent Protein (200-208) (EGFP (200-208)) is a peptide that strongly binds to H2-K, a restricted cytotoxic T lymphocyte (CTL) epitope.

eGFP mRNA-LNP is a lipid nanoparticle encapsulating eGFP mRNA, designed to evaluate RNA delivery, translation efficiency, and cell viability. Upon cell internalization, it expresses Enhanced Green Fluorescent Protein (eGFP), enabling detection through fluorescence microscopy or flow cytometry [1].

eGFP circRNA-LNP, a lipid nanoparticle comprising eGFP circRNA, facilitates studies of RNA delivery, translation efficiency, and cell viability. This compound includes Enhanced Green Fluorescent Protein (eGFP) for expression within cells, detectable via fluorescence microscopy or flow cytometry [1].

AMG-47a is a potent inhibitor of Lck and T cell proliferation. AMG-47a could promote the degradation of the KRAS oncoprotein. AMG-47a selectively reduced the levels of EGFP-KRASG12V protein but did not affect EGFP protein in cells.

Bexin-1 is an inhibitor of Munc13-4 membrane binding which targets the Munc13-4 C2 domain-membrane interface, and inhibits ionomycin-stimulated ANF-EGFP secretion.

2G-HaloAUTAC (Compound tt44), a second-generation autophagy-targeting chimera (2G-HaloAUTAC), enhances the activity of autophagy-targeting chimeras (AUTAC) by substituting the L-Cysteine (L-Cys) linker with alternative structures. This compound demonstrates degradative activity against EGFP-HaloTag protein through an autophagy mechanism.